reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
VIAV VIAVI SOLUTIONS INC
ROLL RBC BEARINGS INCORPORATED
NRIM NORTHRIM BANCORP INC.
KEYS KEYSIGHT TECHNOLOGIES INC
JBT JOHN BEAN TECHNOLOGIES CORPORATION
GLW CORNING INC
EMN EASTMAN CHEMICAL COMPANY
CIEN CIENA CORPORATION
CAMT CAMTEK LTD.
BMI BADGER METER INC.
BEN FRANKLIN RESOURCES INC.
TATT TAT TECHNOLOGIES LTD.
INTT INTEST CORP.
PLSE PULSE BIOSCIENCES
LCUT LIFETIME BRANDS
ISSC INNOVATIVE SOLUTIONS & SUPPORT INC.
SRTS SENSUS HEALTHCARE
FTG111 FLATEXDEGIRO AG
CVCO CAVCO INDUSTRIES INC.
ATGE ADTALEM GLOBAL EDUCATION INC.
JHG JANUS HENDERSON GROUP PLC
BKR BAKER HUGHES COMPANY CLASS A
INS INTELLIGENT SYSTEMS CORP.
AVGO BROADCOM INC.
CSPI CSP INC.
TSSI TSS INC
INMB INMUNE BIO
TARS TARSUS PHARMACEUTICALS
HIMS HIMS AND HERS HEALTH INC (A)
GTLB GITLAB INC
VERV VERVE THERAPEUTICS INC
LNSR LENSAR INC
TEAM ATLASSIAN CORPORATION
BKSY BLACKSKY TECHNOLOGY INC
BBCN39 JPMORGAN BETABUILDERS CANADA BDR
VATE INNOVATE CORP
MNPR MONOPAR THERAPEUTICS INC.
Pompano Veterinary Oncology Partners with Sensus Healthcare to Provide...
Pompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration Full-service medical oncology practice to pioneer the use of SRT to treat companion animals for both home and veterinary clinic visits BOCA RATON, Fla, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, has partnered with Pompano Veterinary Oncology to pione...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
HBI HANESBRANDS INC.
ESE ESCO TECHNOLOGIES INC.
DGX QUEST DIAGNOSTICS INCORPORATED
DAR DARLING INGREDIENTS INC.
FLR FLUOR CORPORATION
HWBK HAWTHORN BANCSHARES
CENX CENTURY ALUMINUM COMPANY
UEIC UNIVERSAL ELECTRONICS INC.
WEYS WEYCO GROUP INC.
PNRG PRIMEENERGY RESOURCES
TPB TURNING POINT BRANDS
SENEA SENECA FOODS CORP. CL A
AA ALCOA CORPORATION
LMB LIMBACH HOLDINGS
SRTS SENSUS HEALTHCARE
ATGE ADTALEM GLOBAL EDUCATION INC.
DESP DESPEGAR.COM CORP.
SMID SMITH MIDLAND
FGBI FIRST GUARANTY BANCSHARES
NVST ENVISTA HOLDINGS
AFRM AFFIRM HOLDINGS
SPNT SIRIUSPOINT LTD
LMND LEMONADE INC
PAY PAYMENTUS HLDGS INC
COIN COINBASE GLOBAL INC
RKLB ROCKET LAB USA INC
PPTA PERPETUA RESOURCES CORP
ROOT ROOT INC
LUNR INTUITIVE MACHINES INC
HIPO HIPPO HLDGS INC
BG BUNGE LIMITED
LB LANDBRIDGE COMPANY LLC
FOA FINANCE OF AMERICA COMPANIES INC.
HOYFY HUHTAMAKI (VAN LEER) OYJ ADR 144A
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Resul...
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer’s request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more tha...
Sensus Healthcare Reports Third Quarter 2024 Financial Results With Re...
Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company spe...
Sensus Healthcare to Host Third Quarter 2024 Financial Results and Bus...
Sensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024 BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a d...
Sensus Healthcare Sells SRT System to Providence Swedish Hospital
Sensus Healthcare Sells SRT System to Providence Swedish Hospital Continues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancers BOCA RATON, Fla., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has shipped an SRT system to Providence Swedish Hospital in Seattle. This sale represents the Company’s latest success in generati...
Sensus Healthcare Reports Second Quarter 2024 Financial Results With R...
Sensus Healthcare Reports Second Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Second Quarter Revenues of $9.2 million compares with $4.5 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $2.1 million compares with negative $1.0 million a year ago“Fair Deal Agreement” recurring revenue program gaining momentum with 15 agreements signed to date Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in high...
Sensus Healthcare Issues Reminder That its Second Quarter 2024 Financi...
Sensus Healthcare Issues Reminder That its Second Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, August 8, 2024 BOCA RATON, Fla. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management wi...
Sensus Healthcare to Host Second Quarter 2024 Financial Results and Bu...
Sensus Healthcare to Host Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 8, 2024 BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a disc...
Sensus Healthcare Reports First Quarter 2024 Financial Results With Re...
Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarterLaunched the “Fair Deal Agreement” recurring revenue program to provide an equipment placement option and complement the fair market value lease program for SRT systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, In...
Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Heal...
Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats First veterinary commercial sale of the SRT-100 outside the U.S. BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm a...
Sensus Healthcare Announces Sale of First SRT-100 Vision™ System to As...
Sensus Healthcare Announces Sale of First SRT-100 Vision™ System to Asia Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024 BOCA RATON, Fla, May 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the sale of the first SRT-100 Vision™ (IG-SRT) system in Asia, to Far Eastern Memorial Hospital in Taiwan. The hospital, which has more than 1,000 beds, is one of the largest private ho...
Sensus Healthcare Issues Reminder That its First Quarter 2024 Financia...
Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024 BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provid...
Sensus Healthcare to Host First Quarter 2024 Financial Results and Bus...
Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024 BOCA RATON, Fla. , April 18, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion ...
Sensus Healthcare to Participate in the 36th Annual Roth Conference
Sensus Healthcare to Participate in the 36th Annual Roth Conference Management will discuss its new “Fair Deal Agreement” for its SRT-100 Vision™ IG-SRT in one-on-one meetings in Dana Point, California on March 18th and 19th BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces management will participate in one-on-one or small group meetings with institutional inv...
Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Visio...
Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting New shared service contract expands the unmatched clinical results achieved with IG-SRT to a broader base of prospective customers Active traffic at the Company’s booth generated a record-high number of sales leads and affirms very strong interest in a better economic choice BOCA RATON, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive...
Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial ...
Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditionsIntroduces recurring revenue model for the SRT-100 Vision™ (IG-SRT) to address dermatologist demand Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncolo...
Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SR...
Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management System.” This new patent covers systems and methods for treating a patient with...
Sensus Healthcare Collaborates with CureRays to Provide Oversight to H...
Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements Physician-run radiation oncology innovator also to research new indications and broaden the market for SRT to include inflammatory diseases BOCA RATON, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a new...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.